Core Viewpoint - Hims & Hers Health Inc. is facing potential securities fraud claims following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and selling unapproved products [2][3]. Group 1: Company Actions and Allegations - Hims & Hers is under investigation for making materially false or misleading statements regarding its GLP-1 offerings and the partnership with Novo Nordisk [3]. - The company allegedly engaged in deceptive marketing practices and sold unapproved compounded versions of semaglutide, leading to significant investor concerns [2][3]. Group 2: Market Reaction - Following the announcement of the termination of the partnership with Novo Nordisk, shares of Hims & Hers experienced a decline of over 34% in intraday trading, indicating heightened investor anxiety regarding regulatory compliance and reputational risks [2]. Group 3: Legal Proceedings - Investors who purchased Hims & Hers securities between April 29, 2025, and June 22, 2025, are eligible to seek appointment as lead plaintiff representatives by the deadline of August 25, 2025 [1].

NEW YORK, July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Centene Corporation ("Centene" or the "Company") (NYSE: CNC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  The investigation concerns whether Centene and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On July 1, 2025, Centene ...

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving argenx SE and its officers or directors [1] Group 1: Regulatory Concerns - On June 30, 2025, the FDA issued an alert regarding argenx's Vyvgart Hytrulo product, indicating a potential risk of "severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy" [2] - The FDA is currently evaluating the need for regulatory action based on reports received [2] Group 2: Market Reaction - Following the FDA alert, argenx's American Depositary Share (ADS) price decreased by $8.92, or 1.59%, closing at $551.22 per ADS on June 30, 2025 [2]

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of BellRing Brands, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - During the second quarter 2025 earnings call, BellRing disclosed that certain customers are optimizing their inventories, leading to a slowdown in sales growth to "low-single-digits" for the third quarter [2] - Following the earnings call, BellRing's stock price dropped by $14.88 per share, or 18.97%, closing at $63.55 on May 6, 2025 [2] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3]

NEW YORK, July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  American Outdoor Brands, Inc. ("American Outdoor" or the "Company") (NASDAQ: AOUT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether American Outdoor and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class ac ...

NEW YORK, July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Unicycive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On June 30 ...

NEW YORK, July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. ("Harrow" or the "Company") (NASDAQ: HROW).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  The investigation concerns whether Harrow and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On May 8, 2025, Harrow issued ...

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in stock price following the termination of its partnership with Novo Nordisk [1][3]. Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell a bundled offering of Wegovy on its platform [2]. Legal Allegations - The class action lawsuit alleges that Hims & Hers and its executives made false or misleading statements and failed to disclose the risks associated with their practices, which jeopardized patient safety [2]. - Novo Nordisk terminated its partnership with Hims & Hers on June 23, 2025, citing deceptive promotion and selling of illegitimate versions of Wegovy [3]. Stock Impact - Following the announcement of the termination of the partnership, Hims & Hers' stock price fell by more than 34% [3]. Class Action Process - Investors who purchased Hims & Hers securities during the specified class period can seek appointment as lead plaintiff in the lawsuit, which allows them to represent the interests of all class members [4].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Petco Health and Wellness Company, Inc. for alleged misrepresentations regarding its ability to achieve sustainable and profitable growth [3]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the Southern District of California on behalf of investors who purchased Petco securities between January 14, 2021, and June 5, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against the Company and certain senior officers [3]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by August 29, 2025, although participation as a lead plaintiff is not required to share in any potential recovery [4]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [4]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since its inception in 1993 and has represented both individual investors and large public and private pension funds [5]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [5].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Sarepta Therapeutics, Inc. for alleged misrepresentations regarding the safety risks of its product ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [3][4]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the Southern District of New York on behalf of investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against Sarepta and certain senior officers [3]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by August 25, 2025, with the option to remain as absent class members if they choose not to take action [5]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large pension funds [6]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].